We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia Rheumatica
Read MoreHide Full Article
Key Takeaways
Novartis gains FDA approval for Cosentyx as the first anti-IL-17 biologic for adults with PMR.
Phase III data showed 40.5% of Cosentyx patients achieved sustained remission at week 52 vs. 20.5% on placebo.
Cosentyx generated $5.25 billion in nine-month 2026 sales, up 6% year over year, as label expansions continue.
Novartis (NVS - Free Report) announced that the FDA has approved Cosentyx (secukinumab) for treating adults with polymyalgia rheumatica (“PMR”) who have had an inadequate response to corticosteroids or cannot tolerate corticosteroid tapering.
Following the latest nod, Cosentyx became the first and only anti-IL-17 biologic to be approved for PMR in the United States, offering a new treatment option for patients with limited alternatives beyond long-term steroid use.
The European Commission approved Cosentyx for the treatment of adults with PMR last month.
Year to date, shares of Novartis have gained 17.7% compared with the industry’s growth of 28.1%.
Image Source: Zacks Investment Research
More on Latest Nod for NVS’ Cosentyx
The FDA approval was based on positive data from the pivotal phase III REPLENISH study. The study met its primary endpoint, with 40.5% of patients who were treated with Cosentyx (150 mg) achieving sustained remission at week 52, compared with 20.5% of patients receiving placebo, following a 24-week steroid tapering regimen.
Treatment with Cosentyx also demonstrated steroid-sparing benefits, while its safety profile remained consistent with the drug's established profile.
PMR is a common inflammatory disease primarily affecting adults over the age of 50 years. Around 966,000 people in the United States live with the condition. Corticosteroids are commonly used as the standard of care, but relapses are frequent, and long-term steroid use can increase the risk of complications, including osteoporosis, cardiovascular disease and diabetes.
The latest approval marks Cosentyx's 11th indication in the United States, further expanding its presence across immune-mediated inflammatory diseases.
NVS’ Cosentyx Other Approved Use
Cosentyx is a fully human biologic that selectively targets and inhibits interleukin-17A. The drug is currently approved for several inflammatory conditions in adults, including psoriatic arthritis (PsA), moderate to severe plaque psoriasis (PsO), ankylosing spondylitis (“AS”), non-radiographic axial spondyloarthritis (nr-axSpA), hidradenitis suppurativa (“HS”) and PMR.
Cosentyx also has pediatric indications, including PsO, juvenile psoriatic arthritis and enthesitis-related arthritis. In the United States, it is additionally approved for pediatric patients aged 12 years and older with moderate-to-severe HS and juvenile AS.
Last week, the Committee for Medicinal Products for Human Use (“CHMP”) rendered a positive opinion recommending marketing authorization for Cosentyx for treating adolescents aged 12 years and older with active moderate-to-severe HS.
A final decision from the EC is expected within two months.
Cosentyx recorded sales worth $5.25 billion in the first nine months of 2026, reflecting an increase of 6% year over year at constant exchange rates. Continuous label expansion for additional indications is likely to boost sales further.
Over the past 30 days, estimates for Vericel’s 2026 earnings per share have risen from 54 cents to 78 cents, while estimates for 2027 have increased from 84 cents to 98 cents during the same time. VCEL shares have surged 60.8% year to date.
Vericel’s earnings beat estimates in three of the trailing four quarters, while meeting the same on the remaining occasion, with the average surprise being 367.50%.
Over the past 30 days, estimates for Eton Pharmaceuticals’ 2026 earnings per share have risen from $1.13 to $1.54, while estimates for 2027 have increased from $1.94 to $2.36 during the same time. ETON shares have skyrocketed 276.4% year to date.
Eton Pharmaceuticals’ earnings beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions, with the average surprise being 80.40%.
Image: Bigstock
NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia Rheumatica
Key Takeaways
Novartis (NVS - Free Report) announced that the FDA has approved Cosentyx (secukinumab) for treating adults with polymyalgia rheumatica (“PMR”) who have had an inadequate response to corticosteroids or cannot tolerate corticosteroid tapering.
Following the latest nod, Cosentyx became the first and only anti-IL-17 biologic to be approved for PMR in the United States, offering a new treatment option for patients with limited alternatives beyond long-term steroid use.
The European Commission approved Cosentyx for the treatment of adults with PMR last month.
Year to date, shares of Novartis have gained 17.7% compared with the industry’s growth of 28.1%.
Image Source: Zacks Investment Research
More on Latest Nod for NVS’ Cosentyx
The FDA approval was based on positive data from the pivotal phase III REPLENISH study. The study met its primary endpoint, with 40.5% of patients who were treated with Cosentyx (150 mg) achieving sustained remission at week 52, compared with 20.5% of patients receiving placebo, following a 24-week steroid tapering regimen.
Treatment with Cosentyx also demonstrated steroid-sparing benefits, while its safety profile remained consistent with the drug's established profile.
PMR is a common inflammatory disease primarily affecting adults over the age of 50 years. Around 966,000 people in the United States live with the condition. Corticosteroids are commonly used as the standard of care, but relapses are frequent, and long-term steroid use can increase the risk of complications, including osteoporosis, cardiovascular disease and diabetes.
The latest approval marks Cosentyx's 11th indication in the United States, further expanding its presence across immune-mediated inflammatory diseases.
NVS’ Cosentyx Other Approved Use
Cosentyx is a fully human biologic that selectively targets and inhibits interleukin-17A. The drug is currently approved for several inflammatory conditions in adults, including psoriatic arthritis (PsA), moderate to severe plaque psoriasis (PsO), ankylosing spondylitis (“AS”), non-radiographic axial spondyloarthritis (nr-axSpA), hidradenitis suppurativa (“HS”) and PMR.
Cosentyx also has pediatric indications, including PsO, juvenile psoriatic arthritis and enthesitis-related arthritis. In the United States, it is additionally approved for pediatric patients aged 12 years and older with moderate-to-severe HS and juvenile AS.
Last week, the Committee for Medicinal Products for Human Use (“CHMP”) rendered a positive opinion recommending marketing authorization for Cosentyx for treating adolescents aged 12 years and older with active moderate-to-severe HS.
A final decision from the EC is expected within two months.
Cosentyx recorded sales worth $5.25 billion in the first nine months of 2026, reflecting an increase of 6% year over year at constant exchange rates. Continuous label expansion for additional indications is likely to boost sales further.
NVS Zacks Rank & Other Stocks to Consider
Novartis currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Vericel (VCEL - Free Report) and Eton Pharmaceuticals (ETON - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.a
Over the past 30 days, estimates for Vericel’s 2026 earnings per share have risen from 54 cents to 78 cents, while estimates for 2027 have increased from 84 cents to 98 cents during the same time. VCEL shares have surged 60.8% year to date.
Vericel’s earnings beat estimates in three of the trailing four quarters, while meeting the same on the remaining occasion, with the average surprise being 367.50%.
Over the past 30 days, estimates for Eton Pharmaceuticals’ 2026 earnings per share have risen from $1.13 to $1.54, while estimates for 2027 have increased from $1.94 to $2.36 during the same time. ETON shares have skyrocketed 276.4% year to date.
Eton Pharmaceuticals’ earnings beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions, with the average surprise being 80.40%.